Alveo was founded by Ron Chiarello in 2015.

Who are Alveo's investors?

Alveo's investors include Black Diamond Ventures, Celesta Capital, Celesta Capital, Civilization Ventures Management, Llc, Partners Resolute, SUPPLY CHANGE CAPITAL.

How much funding has Alveo raised?

Alveo has disclosed $63.6M raised across 2 rounds.

Where is Alveo headquartered?

Alveo is headquartered in Alameda, US.

Alveo

Alameda, US · Founded 2015 · Delaware corporation · 66 employees on LinkedIn · 6 known investors

Find your way into Alveo

1,103 people in our graph share verified history with the Alveo team — schools, employers, funds. One of them is your warm intro.

Lu Wangunlockedknows Erik Tyrrell-Knott · together at Thermo Fisher Scientific (overlapped)

×4knows the team · via Thermo Fisher Scientific

×2knows the team · via Vassar College

knows the team · via Wisconsin School of Business

knows the team · via Atonarp

×2knows the team · via West Health

Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.

AgTech Biotech Medical Devices

Founders & leadership

Alveo was founded in 2015 by Ron Chiarello.

Ron Chiarello Founder, Board Chair and CEO2015–2021Ron Chiarello is a physicist with background from Argonne and Stanford who has spent two decades building companies in diagnostics, biotech, AI, and quantum hardware, with cumulative fundraising exceeding $250 million and an XPRIZE award.

Michael AicherExecutive

Shaun HoltChairman of the Board & Chief Executive Officer

Erik Tyrrell-Knott President & Chief Business OfficerErik Tyrrell-Knott is President and Chief Business Officer of Alveo Technologies, which develops portable molecular diagnostic analyzers for point-of-care infectious disease detection. He has held business development and corporate development roles in life sciences companies ranging from startups to established global firms.

ScottChief Commercial Officer

Slava Elagin Executive (R&D/Operations)Slava Elagin is an executive with experience in in vitro diagnostics, medical devices, and biotechnology, holding advanced degrees (MBA and PhD) and having held leadership roles including VP and C-suite positions at publicly traded and private organizations. He brings expertise in R&D, operations, regulatory affairs, FDA interactions, and product development from research through commercialization in areas including molecular diagnostics and point-of-care testing.

MarcusSenior Vice President of Software Engineering

Board

Isaac BlechBoard director

Robin SteeleBoard director

Lawrence BlattBoard director

Investors · 6

Black Diamond Ventures✓ confirmed by AlveoGlendale · $2M – $10M

How we know: the company's own site · Not right? Tell us

Celesta Capitallisted by Celesta CapitalMenlo Park · $5M – $10M

How we know: Celesta Capital's portfolio page · board seat on SEC Form D · Not right? Tell us

Celesta Capitallisted by Celesta CapitalSan Francisco

Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M

How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us

Partners Resolutelisted by Partners ResoluteChicago

How we know: Partners Resolute's portfolio page · Not right? Tell us

SUPPLY CHANGE CAPITALreportedChicago · $200K – $1M

How we know: the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$63.6M disclosed across 2 rounds · 2016–2021

▶$16MraisedMar 2021 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ronald ChiarelloExecutive Officer, Director
Robin SteeleDirector
Lawrence BlattDirector
Julianne AverillExecutive Officer
Yuh-Min ChiangExecutive Officer
Nicholas BrathwaiteDirector

Offering amount: $30.1M
Amount sold: $16M
First sale: Mar 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$47.6MraisedFeb 2018 · 248 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Isaac BlechDirector
Robin SteeleDirector
Michael AicherExecutive Officer, Director
Ron ChiarelloExecutive Officer, Director
Lawrence BlattDirector

Offering amount: $47.6M
Amount sold: $47.6M
Sales commissions: $3.1M
Placement agents: Maxim Group LLC
First sale: Nov 2016
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Cerecor Inc.6 shared keywordsAvalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.

Labcorp5 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.

Alveolusbio5 shared keywordsAlveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.

Companies competing with Alveo for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Alveo do?: Alveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.
Who founded Alveo?: Alveo was founded by Ron Chiarello in 2015.
Who are Alveo's investors?: Alveo's investors include Black Diamond Ventures, Celesta Capital, Celesta Capital, Civilization Ventures Management, Llc, Partners Resolute, SUPPLY CHANGE CAPITAL.
How much funding has Alveo raised?: Alveo has disclosed $63.6M raised across 2 rounds.
Where is Alveo headquartered?: Alveo is headquartered in Alameda, US.